Memantine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Kour, Kamalpreet ^a   Kaur, Rupinder ^b   Singh, Jasvinder ^c  

^a LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^b Meanwood   (United Kingdom)

^c The Walker Street Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MEMANTINE; PLACEBO;

ARTICLE; CLINICAL EFFECTIVENESS; COGNITION; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIA LIKE PSYCHOSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 85042902837     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010552     Document Type: Article

References (42)

1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
2. Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. PharmacoEconomics 2008;26(2):149-62.
3. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
4. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des Indices d'efficacite]. Therapie 1999;54(4):405-11.
5. Bondi C, Matthews M, Moghaddam B. Glutamatergic animal models of schizophrenia. Current Pharmaceutical Design 2012;18(12):1593-604.
6. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;33(10):681-90.
7. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. Journal of Neurochemistry 2006;97(6):1611-26.
8. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
9. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
10. Dominguez E, Chin TY, Chen CP, Wu TY. Management of moderate to severe Alzheimer's disease: focus on memantine. Taiwanese Journal of Obstetrics & Gynecology 2011;50(4):415-23.
11. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
13. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: Methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
14. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
15. Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, et al.Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophrenia Bulletin 2008;34(2):393-401.
16. Gonda X. Basic pharmacology of NMDA receptors. Current pharmaceutical design 2012;18(12):1558-67.
17. Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophrenia Bulletin 2012;38(5):950-7.
18. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
20. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Hollmann M, Heinemann S. Cloned glutamate receptors. Annual Review of Neuroscience 1994;17:31-108.
22. Hutton Jane L. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
23. Javitt DC. Glutamatergic theories of schizophrenia. The Israel Journal of Psychiatry and Related Sciences 2010;47(1):4-16.
24. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
25. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8.
26. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71.
27. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91.
28. Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Review of Neurotherapeutics 2011;11(10):1359-70.
29. Maekawa M, Namba T, Suzuki E, Yuasa S, Kohsaka S, Uchino S. NMDA receptor antagonist memantine promotes cell proliferation and production of mature granule neurons in the adult hippocampus. Neuroscience Research 2009;63(4):259-66.
30. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
31. Monaghan DT, Jane DE. Pharmacology of NMDA Receptors. Biology of the NMDA Receptor 2009.
32. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363(9426):2063-72.
33. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 1995;52(12):998-1007.
34. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
35. Picchioni MM, Murray RM. Schizophrenia. BMJ (Clinical research ed.) 2007;335(7610):91-5.
36. Rund BR. Is there a degenerative process going on in the brain of people with Schizophrenia?. Frontiers in Human Neuroscience 2009;3:36.
37. Schwartz TL, Sachdeva S, Stahl SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Current pharmaceutical design 2012;18(12):1580-92.
38. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
39. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. Pharmacological Research: The Official Journal of the Italian Pharmacological Society 2005;51(1):1-17.
40. Stone JM, Pilowsky LS. Novel targets for drugs in schizophrenia. CNS & Neurological Disorders Drug Targets 2007;6(4):265-72.
41. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
42. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.